



**ESSEX BIO-TECHNOLOGY LIMITED**  
億勝生物科技有限公司

**Press Release**

**ESSEX BIO-TECHNOLOGY LIMITED APPOINTED FIVE RENOUNCED  
EYE SURGEONS AND PHARMACEUTICAL EXPERTS TO FORM AN  
ADVISORY BOARD**

Hong Kong, 19 August 2005 — ESSEX BIO-TECHNOLOGY LIMITED (“Essex” or the “Group”; Stock Code: 8151) today announced that its major subsidiary, Zhuhui Essex Bio-Pharmaceutical Company Limited has appointed five renounced eye surgeons and pharmaceutical experts to form an advisory board (the “Advisory Board”). Their appointment is for a period a three years commencing in August 2005.

The five (5) Advisory Board members are:

**Professor Zhao Jialiang** - Professor Zhao is the Director of the Board of Ophthalmology of the Chinese Medical Association, who specializes in the research of ophthalmic epidemiology and the treatment of glaucoma as well as the prevention of blindness.

**Professor Chen Jiaqi** - Professor Chen is the tutor of doctors in the Center of Ophthalmology of Sun Yat-sen University of Medical Science, who specializes in the research and treatment of keratopathy.

**Professor Xu Jintang** - Professor Xu is the tutor of doctors of ophthalmology in Jinan University, who specializes in the research and treatment of keratopathy.

**Professor Chen Zuji** - Professor Chen, a famous expert of ophthalmic pharmacology in China, is the Director of the Institute of Ophthalmology of Henan Province, who specializes in the research of ophthalmic drugs.

**Professor Sun Xinghuai** - Professor Sun is the tutor of doctors in the Hospital of Eye, Ear, Nose and Throat affiliated to Fudan University, who specializes in the research and treatment of glaucoma.

The Advisory Board is to provide strategic input, guidance and connections to the Group for its pursuits of development and marketing of drugs for the treatment and healing of eye wounds and diseases.

“On behalf of the directors, I welcome the 5 advisors on board. The Group is particularly honored having the renounced experts to guide the Group expanding its R&D and marketing on drugs that are for the treatment and healing of eye wounds and diseases”

“The Group has initial marketing success on one of its flagship products, the Beifushu, for the treatment and healing of corneal wounds and diseases. It is the direction of the Group to capitalize on the success and to develop a series of drugs for the treatment of eye wounds and diseases over the next 5 years.”, said Chairman Dr Patrick NGIAM.

***About Essex Bio-Technology Limited:***

Essex Bio-Technology Limited (“Essex”) was listed on the Growth Enterprise Market (GEM) of The Stock Exchange of Hong Kong Limited on 27 June 2001. Essex was the first genetic engineering drug developer, manufacturer and distributor listed on GEM. Essex specializes in biopharmaceutical drug development based on recombinant DNA technology.

Essex was principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. Essex also engaged in the research and development of biopharmaceutical products for the treatment of duodenal ulcers and nervous system damages and diseases, as well as other optical pharmaceutical projects.

Essex’s flagship products are Beifuji and Beifushu for the treatment and healing of surface wounds and corneal wounds respectively. Beifuji and Beifushu are all classified as category I biopharmaceutical products which are the first biopharmaceutical products in this category approved for commercial deployment in the PRC.

—End—

***For more information, please contact:***

**Essex Bio-Technology Limited**

Email : [essex@essexbio.com](mailto:essex@essexbio.com)

Tel : (852) 2587-7838